Cargando…
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) is commonly accompanied by other cardiovascular disease (CVD) risk factors, such as hypertension, obesity, and dyslipidemia. Furthermore, CVD is the most common cause of death in people with T2DM. It is therefore of critical importance to minimize the risk of macrovas...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043722/ https://www.ncbi.nlm.nih.gov/pubmed/24920930 http://dx.doi.org/10.2147/DMSO.S61438 |
_version_ | 1782318975431999488 |
---|---|
author | Lorber, Daniel |
author_facet | Lorber, Daniel |
author_sort | Lorber, Daniel |
collection | PubMed |
description | Type 2 diabetes mellitus (T2DM) is commonly accompanied by other cardiovascular disease (CVD) risk factors, such as hypertension, obesity, and dyslipidemia. Furthermore, CVD is the most common cause of death in people with T2DM. It is therefore of critical importance to minimize the risk of macrovascular complications by carefully managing modifiable CVD risk factors in patients with T2DM. Therapeutic strategies should include lifestyle and pharmacological interventions targeting hyperglycemia, hypertension, dyslipidemia, obesity, cigarette smoking, physical inactivity, and prothrombotic factors. This article discusses the impact of modifying these CVD risk factors in the context of T2DM; the clinical evidence is summarized, and current guidelines are also discussed. The cardiovascular benefits of smoking cessation, increasing physical activity, and reducing low-density lipoprotein cholesterol and blood pressure are well established. For aspirin therapy, any cardiovascular benefits must be balanced against the associated bleeding risk, with current evidence supporting this strategy only in certain patients who are at increased CVD risk. Although overweight, obesity, and hyperglycemia are clearly associated with increased cardiovascular risk, the effect of their modification on this risk is less well defined by available clinical trial evidence. However, for glucose-lowering drugs, further evidence is expected from several ongoing cardiovascular outcome trials. Taken together, the evidence highlights the value of early intervention and targeting multiple risk factors with both lifestyle and pharmacological strategies to give the best chance of reducing macrovascular complications in the long term. |
format | Online Article Text |
id | pubmed-4043722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40437222014-06-11 Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus Lorber, Daniel Diabetes Metab Syndr Obes Review Type 2 diabetes mellitus (T2DM) is commonly accompanied by other cardiovascular disease (CVD) risk factors, such as hypertension, obesity, and dyslipidemia. Furthermore, CVD is the most common cause of death in people with T2DM. It is therefore of critical importance to minimize the risk of macrovascular complications by carefully managing modifiable CVD risk factors in patients with T2DM. Therapeutic strategies should include lifestyle and pharmacological interventions targeting hyperglycemia, hypertension, dyslipidemia, obesity, cigarette smoking, physical inactivity, and prothrombotic factors. This article discusses the impact of modifying these CVD risk factors in the context of T2DM; the clinical evidence is summarized, and current guidelines are also discussed. The cardiovascular benefits of smoking cessation, increasing physical activity, and reducing low-density lipoprotein cholesterol and blood pressure are well established. For aspirin therapy, any cardiovascular benefits must be balanced against the associated bleeding risk, with current evidence supporting this strategy only in certain patients who are at increased CVD risk. Although overweight, obesity, and hyperglycemia are clearly associated with increased cardiovascular risk, the effect of their modification on this risk is less well defined by available clinical trial evidence. However, for glucose-lowering drugs, further evidence is expected from several ongoing cardiovascular outcome trials. Taken together, the evidence highlights the value of early intervention and targeting multiple risk factors with both lifestyle and pharmacological strategies to give the best chance of reducing macrovascular complications in the long term. Dove Medical Press 2014-05-23 /pmc/articles/PMC4043722/ /pubmed/24920930 http://dx.doi.org/10.2147/DMSO.S61438 Text en © 2014 Lorber. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Lorber, Daniel Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus |
title | Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus |
title_full | Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus |
title_fullStr | Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus |
title_full_unstemmed | Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus |
title_short | Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus |
title_sort | importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043722/ https://www.ncbi.nlm.nih.gov/pubmed/24920930 http://dx.doi.org/10.2147/DMSO.S61438 |
work_keys_str_mv | AT lorberdaniel importanceofcardiovasculardiseaseriskmanagementinpatientswithtype2diabetesmellitus |